Drug-Repositioning Approach for the Discovery of Anti-Influenza Virus Activity of Japanese Herbal (Kampo) Medicines In Vitro: Potent High Activity of Daio-Kanzo-To
Table 1
Anti-influenza virus activity of commercially available Kampo medicines.
IC50 (μg/mL
CC50 (μg/mL
Remarks
Daio-kanzo-to (TJ-84)
10.5±5.5
71.6±9.1
6.8
Tsumura & Co.
Mao-to (EK-27)
45.6±11.3
>1000
>21.9
Kracie Holdings, Ltd.
Mao-to (TJ-27)
53.3±0.7
264.2±15.6
5.0
Tsumura & Co.
Mao-to (N27)
84.1±24.1
>1000
>11.9
Kotaro pharmaceutical Co., Ltd.
Bofu-tsusho-san (TJ-62)
170.0±1.5
>333.3
>2.0
Tsumura & Co.
Kakkon-to (TJ-1)
175.7±16.9
>333.3
>1.9
Tsumura & Co.
Dai-kenchu-to (TJ-100)
>1000
>1000
N/
Tsumura & Co.
Oseltamivir
2.1±0.4
>137
>65.2
% inhibitory concentration against A/WSN/33 virus. % cytotoxic concentration for MDCK cells. ratio of CC50 to IC50. applicable.
